“Anti-PD-1 immune checkpoint blockade-based therapy using pembrolizumab in a patient with high-grade glioblastoma”, Biomed. Res. Ther., vol. 10, no. 5, pp. 5680–5685, May 2023, doi: 10.15419/bmrat.v10i5.809.